Somsundar Veppil Muralidharan

Somsundar Veppil Muralidharan

Auto-generated profile, based on publicly available information

Somsundar Veppil Muralidharan

Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SMSanhita Mitra
Sanhita Mitra
SMSomsundar Veppil Muralidharan
Somsundar Veppil Muralidharan
MMMirco Di Marco
Mirco Di Marco
PJPrasanna Kumar Juvvuna
Prasanna Kumar Juvvuna
SKSubazini Thankaswamy Kosalai
Subazini Thankaswamy Kosalai
CKChandrasekhar Kanduri
Chandrasekhar Kanduri
Neuroblastoma has a low mutation rate for the p53 gene. Alternative ways of p53 inactivation have been proposed in neuroblastoma, such as abnormal cytoplasmic accumulation of wild-type p53. However, mechanisms leading to p53 inactivation via cytoplasmic accumulation are not well investigated. Here we show that the neuroblastoma risk-associated locus 6p22.3-derived tumor suppressor NBAT1 is a p53-responsive lncRNA that regulates p53 subcellular levels. Low expression of NBAT1 provided resistance to genotoxic drugs by promoting p53 accumulation in cytoplasm and loss from mitochondrial and nuclear compartments. Depletion of NBAT1 altered CRM1 function and contributed to the loss of p53-dependent nuclear gene expression during genotoxic drug treatment. CRM1 inhibition rescued p53-dependent nuclear functions and sensitized NBAT1-depleted cells to genotoxic drugs. Combined inhibition of CRM1 and MDM2 was even more effective in sensitizing aggressive neuroblastoma cells with p53 cytoplasmic accumulation. Thus, our mechanistic studies uncover an NBAT1-dependent CRM1/MDM2-based potential combination therapy for patients with high-risk neuroblastoma. Significance: This study shows how a p53-responsive lncRNA mediates chemotherapeutic response by modulating nuclear p53 pathways and identifies a potential treatment strategy for patients with high-risk neuroblastoma.

10 August 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SMSomsundar Veppil Muralidharan
Somsundar Veppil Muralidharan
BEBerglind Osk Einarsdottir
Berglind Osk Einarsdottir
JBJoydeep Bhadury
Joydeep Bhadury
MLMattias F Lindberg
Mattias F Lindberg
JWJin Wu
Jin Wu
Jonas NilssonJonas Nilsson
Jonas Nilsson
Metastatic malignant melanoma continues to be a challenging disease despite clinical translation of the comprehensive understanding of driver mutations and how melanoma cells evade immune attack. In Myc-driven lymphoma, efficacy of epigenetic inhibitors of the bromodomain and extra-terminal domain (BET) family of bromodomain proteins can be enhanced by combination therapy with inhibitors of the DNA damage response kinase ATR. Whether this combination is active in solid malignancies like melanoma, and how it relates to immune therapy, has not previously investigated. To test efficacy and molecular consequences of combination therapies cultured melanoma cells were used. To assess tumor responses to therapies in vivo we use patient-derived xenografts and B6 mice transplanted with B16F10 melanoma cells. Concomitant inhibition of BET proteins and ATR of cultured melanoma cells resulted in similar effects as recently shown in lymphoma, such as induction of apoptosis and p62, implicated in autophagy, senescence-associated secretory pathway and ER stress. In vivo, apoptosis and suppression of subcutaneous growth of patient-derived melanoma and B16F10 cells were observed. Our data suggest that ATRI/BETI combination therapies are effective in melanoma.

22 June 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
SMSomsundar V Muralidharan
Somsundar V Muralidharan
LNLisa M Nilsson
Lisa M Nilsson
MLMattias F Lindberg
Mattias F Lindberg
Jonas NilssonJonas Nilsson
Jonas Nilsson
Chk1 kinase is downstream of the ATR kinase in the sensing of improper replication. Previous cell culture studies have demonstrated that Chk1 is essential for replication. Indeed, Chk1 inhibitors are efficacious against tumors with high-level replication stress such as Myc-induced lymphoma cells. Treatment with Chk1 inhibitors also combines well with certain chemotherapeutic drugs, and effects associate with the induction of DNA damage and reduction of Chk1 protein levels. Most studies of Chk1 function have relied on the use of inhibitors. Whether or not a mouse or cancer cells could survive if a kinase-dead form of Chk1 is expressed has not been investigated before. Here, we generate a mouse model that expresses a kinase-dead (D130A) allele in the mouse germ line. We find that this mouse is overtly normal and does not have problems with erythropoiesis with aging as previously been shown for a mouse expressing one null allele. However, similar to a null allele, homozygous kinase-dead mice cannot be generated, and timed pregnancies of heterozygous mice suggest lethality of homozygous blastocysts at around the time of implantation. By breeding the kinase-dead Chk1 mouse with a conditional allele, we are able to demonstrate that expression of only one kinase-dead allele, but no wild-type allele, of Chek1 is lethal for Myc-induced cancer cells. Finally, treatment of melanoma cells with tumor-infiltrating T cells or CAR-T cells is effective even if Chk1 is inhibited, suggesting that Chk1 inhibitors can be safely administered in patients where immunotherapy is an essential component of the arsenal against cancer.

31 March 2023
Verified
Other
Open access
SMSanhita Mitra
Sanhita Mitra
SMSomsundar Veppil Muralidharan
Somsundar Veppil Muralidharan
MMMirco Di Marco
Mirco Di Marco
PJPrasanna Kumar Juvvuna
Prasanna Kumar Juvvuna
SKSubazini Thankaswamy Kosalai
Subazini Thankaswamy Kosalai
CKChandrasekhar Kanduri
Chandrasekhar Kanduri
Differentially expressed genes in SH-SY5Y neuroblastoma cells after treatment with nutlin-3a, as detected by RNA-seq.

31 March 2023
Verified
Other
Open access
SMSanhita Mitra
Sanhita Mitra
SMSomsundar Veppil Muralidharan
Somsundar Veppil Muralidharan
MMMirco Di Marco
Mirco Di Marco
PJPrasanna Kumar Juvvuna
Prasanna Kumar Juvvuna
SKSubazini Thankaswamy Kosalai
Subazini Thankaswamy Kosalai
CKChandrasekhar Kanduri
Chandrasekhar Kanduri
Neuroblastoma has a low mutation rate for the p53 gene. Alternative ways of p53 inactivation have been proposed in neuroblastoma, such as abnormal cytoplasmic accumulation of wild-type p53. However, mechanisms leading to p53 inactivation via cytoplasmic accumulation are not well investigated. Here we show that the neuroblastoma risk-associated locus 6p22.3-derived tumor suppressor NBAT1 is a p53-responsive lncRNA that regulates p53 subcellular levels. Low expression of NBAT1 provided resistance to genotoxic drugs by promoting p53 accumulation in cytoplasm and loss from mitochondrial and nuclear compartments. Depletion of NBAT1 altered CRM1 function and contributed to the loss of p53-dependent nuclear gene expression during genotoxic drug treatment. CRM1 inhibition rescued p53-dependent nuclear functions and sensitized NBAT1-depleted cells to genotoxic drugs. Combined inhibition of CRM1 and MDM2 was even more effective in sensitizing aggressive neuroblastoma cells with p53 cytoplasmic accumulation. Thus, our mechanistic studies uncover an NBAT1-dependent CRM1/MDM2-based potential combination therapy for patients with high-risk neuroblastoma.Significance:This study shows how a p53-responsive lncRNA mediates chemotherapeutic response by modulating nuclear p53 pathways and identifies a potential treatment strategy for patients with high-risk neuroblastoma.

31 March 2023
Verified
Other
Open access
SMSanhita Mitra
Sanhita Mitra
SMSomsundar Veppil Muralidharan
Somsundar Veppil Muralidharan
MMMirco Di Marco
Mirco Di Marco
PJPrasanna Kumar Juvvuna
Prasanna Kumar Juvvuna
SKSubazini Thankaswamy Kosalai
Subazini Thankaswamy Kosalai
CKChandrasekhar Kanduri
Chandrasekhar Kanduri
Differentially expressed genes in SH-SY5Y neuroblastoma cells after treatment with nutlin-3a, as detected by RNA-seq.